Neostigmine Injection BP

Quick links

Choose a section

Quick links to important sections

Advertisements

Neostigmine Injection BP

Advertisements
Advertisements

Overview of Neostigmine Injection BP

What is Neostigmine Injection BP?

Neostigmine Injection BP is a pharmaceutical formulation containing neostigmine methylsulfate, a medication that belongs to a class of compounds known as cholinesterase inhibitors. It is a synthetic quaternary ammonium compound designed for parenteral administration, meaning it is delivered via injection rather than through the digestive tract.

Classification and Mechanism

As a reversible acetylcholinesterase inhibitor, neostigmine works by slowing the breakdown of acetylcholine, a naturally occurring neurotransmitter in the body. Acetylcholine is responsible for transmitting signals between nerve cells and muscles. By inhibiting the enzyme (acetylcholinesterase) that normally clears acetylcholine from the neuromuscular junction, neostigmine allows the neurotransmitter to accumulate and exert a more prolonged effect on muscle receptors.

Therapeutic Purpose

The primary role of Neostigmine Injection BP is to improve muscle tone and facilitate neuromuscular transmission. It is most commonly utilized in clinical settings to address conditions where muscle weakness is a primary concern or where the normal signaling between nerves and muscles has been interrupted.

Historically and clinically, this medication is associated with the management of certain chronic autoimmune neuromuscular diseases and is frequently used in hospital environments to reverse the effects of specific types of muscle relaxants used during surgical procedures. By enhancing the availability of acetylcholine, it helps restore normal muscle function and strength.

Regulatory References

  1. Neostigmine on WHO Essential Medicines List
Advertisements

What side effects are possible with Neostigmine Injection BP?

Neostigmine Injection BP can cause side effects, which are generally related to its mechanism of action and involve an increase in cholinergic activity throughout the body. The majority of these effects can be prevented or managed by co-administering an anticholinergic drug, such as atropine or glycopyrrolate, which is often done before or simultaneously with neostigmine.

Common Side Effects

These effects are frequently reported and often relate to increased bodily secretions and gastrointestinal motility:

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramps, increased salivation, and flatulence.
  • Other: Increased sweating, muscle cramps, muscle twitching (fasciculations), and miosis (constriction of the pupil).

Serious Side Effects and Safety Warnings

Serious effects requiring immediate medical attention are less common but include:

  • Cardiovascular: Bradycardia (slow heart rate), hypotension (low blood pressure), irregular heartbeat (arrhythmia), or, rarely, cardiac arrest. Patients with pre-existing heart conditions are at increased risk.
  • Respiratory: Bronchospasm (tightening of the airways), increased bronchial secretions, and difficulty breathing.
  • Hypersensitivity: Allergic reactions, including a severe reaction known as anaphylaxis, which may present as rash, hives, swelling of the face/throat, or severe dizziness.
  • Neuromuscular: Significant, generalized muscle weakness that may affect the ability to breathe, which can be a sign of a cholinergic crisis due to overdosage.

Contraindications

Neostigmine Injection BP must not be used in patients with a known hypersensitivity to neostigmine or any other ingredient in the product. It is also contraindicated in the presence of mechanical obstruction of the gastrointestinal or urinary tract.

Advertisements

Overdose and Emergency Response

Overdosage of Neostigmine Injection BP is officially documented by regulatory authorities as a severe state known as Cholinergic Crisis. This crisis results from the overstimulation of the body’s neuromuscular and glandular systems. Officially recognized clinical manifestations include profound muscarinic effects such as excessive salivation, lacrimation, sweating (diaphoresis), constricted pupils (miosis), nausea, vomiting, diarrhoea, and significant abdominal cramping.

A critical risk documented in official labeling is the potential for life-threatening outcomes affecting the cardiovascular and respiratory systems. These may include severe bradycardia (slow heart rate), profound hypotension, and the critical danger of respiratory paralysis due to severe muscle weakness. Additionally, excessive bronchial secretions and bronchospasm can compromise breathing.

In the event of any suspected overdose, government-mandated instructions require that medical help be sought immediately. Emergency management involves symptomatic and supportive treatment, including necessary procedures like airway maintenance and mechanical ventilation if respiratory function is compromised. Atropine Sulfate is officially documented as the necessary treatment to counteract the most severe muscarinic effects. Due to cardiovascular risks, continuous cardiac monitoring is often required during management, as specified in regulatory information.

Advertisements

Therapeutic Uses of Neostigmine Injection BP

Main Uses of Neostigmine Injection BP

Neostigmine Injection BP is a medication that belongs to a group of drugs known as cholinesterase inhibitors. Its primary function is to increase the levels of acetylcholine, a chemical messenger in the body that is essential for proper communication between nerves and muscles.

Reversal of Neuromuscular Blockade

The most frequent use of Neostigmine Injection BP is in the field of anesthesia. During surgical procedures, muscle relaxants (neuromuscular blocking agents) are often administered to keep the muscles still and facilitate surgery. Once the procedure is complete, Neostigmine is used to reverse the effects of these muscle relaxants, helping the patient regain muscle strength and the ability to breathe independently.

Management of Myasthenia Gravis

Neostigmine is also utilized in the management of myasthenia gravis, a chronic autoimmune neuromuscular disease. This condition causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body. By preventing the breakdown of acetylcholine, Neostigmine helps improve muscle tone and reduces muscle weakness in patients with this condition.

Other Uses

In specific clinical settings, Neostigmine may be used to treat certain functional issues of the digestive system or the bladder, such as:

  • Paralytic ileus: A condition where the normal muscle contractions of the intestines stop, leading to a blockage.
  • Postoperative urinary retention: Helping the bladder muscles contract to allow for urination after surgery when other causes of retention have been ruled out.

Benefits of Neostigmine Injection BP

The primary benefit of Neostigmine Injection BP is its ability to restore normal muscle function in situations where nerve-to-muscle signaling has been impaired.

  • Restoration of Strength: By increasing the availability of acetylcholine at the junction where nerves meet muscles, it allows for more effective muscle contractions.
  • Surgical Recovery: It plays a critical role in the safe transition from a state of induced muscle relaxation back to normal physical activity following surgery.
  • Improved Quality of Life in Chronic Conditions: For individuals with myasthenia gravis, the medication can help manage daily symptoms of fatigue and muscle failure, supporting better mobility and physical function.
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility to use Neostigmine Injection BP is strictly governed by official regulatory contraindications and mandated cautions across specific patient populations, including Adults and Pediatric Patients for approved uses.

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Neostigmine Methylsulfate.
  • Patients with mechanical obstruction of the intestinal or urinary tracts.
  • Patients with peritonitis or doubtful bowel viability.

Condition-specific eligibility rules:

  • Cardiovascular Conditions: Use requires caution in patients with cardiac arrhythmias, coronary artery disease, or recent acute coronary syndrome (e.g., myocardial infarction).
  • Respiratory/Organ Impairment: Use requires extreme caution in patients with bronchial asthma. Caution is advised in patients with renal impairment due to prolonged drug elimination.
  • Older Adults (Geriatric): Use requires caution as they may be more susceptible to dysrhythmias.

Pregnancy and lactation eligibility status:

  • Pregnancy: The drug should be given only if clearly needed, as anticholinesterase agents may cause uterine irritability or induce premature labor near term.
  • Lactation: Caution should be exercised as it is not known whether the medicine is excreted in human milk.

Eligibility Classifications

Official regulatory documents classify eligibility using strict terminology, including Contraindicated (absolute prohibition), Use with Caution (special monitoring required), and Use Only if Clearly Needed (conditional use in pregnancy).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines clinically significant interactions for Neostigmine Injection BP, as documented in official regulatory information.


Contraindicated and High-Risk Combinations

  • Depolarizing Neuromuscular Blockers (e.g., Suxamethonium): Neostigmine is contraindicated during the Phase I block induced by these agents as it may prolong the neuromuscular blockade, leading to respiratory depression.
  • Inhaled Anesthetics (e.g., Halothane, Cyclopropane): Neostigmine should be administered only after withdrawal of these agents to avoid potentiating their vagotonic effects.

Pharmacodynamic Interactions

Interacting Product Category Effect on Neostigmine Therapy Regulatory Note
Anticholinergic Agents (e.g., Atropine, Glycopyrrolate) Antagonizes muscarinic side effects. Must be given prior to or concomitantly with Neostigmine.
Non-depolarizing Blockers (e.g., Vecuronium, Tubocurarine) Reverses the effects. Used therapeutically for post-operative recovery.
Aminoglycoside Antibiotics (e.g., Neomycin) May reduce effectiveness of Neostigmine. Interference with neuromuscular transmission.
Certain Drugs Affecting Neuromuscular Transmission May reduce effectiveness. Includes Quinine, Chloroquine, Corticosteroids, and Parenteral Magnesium.

Pharmacokinetic and Population Considerations

Official labeling advises caution when Neostigmine is used with medicines that may alter the activity of metabolizing enzymes or transporters. While specific details on changes to drug exposure (AUC/Cmax) are not routinely documented, the risk of altered activity is noted. Furthermore, cholinesterase inhibitors may cause uterine irritability when given near term, which is an important interaction-related consideration for pregnancy.

Advertisements

Mechanism of Action

Enzyme-Mediated Signaling Inhibition

Neostigmine Injection reversibly inhibits the enzyme acetylcholinesterase ( AChE). This biochemical interaction prevents the rapid hydrolysis of the neurotransmitter acetylcholine ( ACh) within the synaptic cleft, leading to an elevated and sustained local ACh concentration.


Enhanced Cholinergic Receptor Activation

The resultant increase in ACh concentration prolongs and intensifies its effect on both nicotinic and muscarinic cholinergic receptors. This enhanced agonism at the neuromuscular junction (a nicotinic domain) is essential for generating increased cholinergic signaling, promoting membrane depolarization and sustained muscle fiber activation.


Peripheral Autonomic Pathway Modulation

Heightened ACh levels also influence the parasympathetic nervous system (a muscarinic domain). This engagement of autonomic mechanisms leads to altered downstream effector responses in tissues such as smooth muscle and glandular cells, resulting in changes to contractility and secretory activity across visceral systems.

Advertisements

Dosage and Administration Information

How to Use Neostigmine Injection BP: Administration Guidelines

Neostigmine Injection (Neostigmine Methylsulfate) is administered strictly by a healthcare professional via authorized routes. The medicine is available as a sterile solution for injection in various concentrations, such as 0.5 mg/mL or 1 mg/mL.


Approved Routes of Administration

The approved methods for administering Neostigmine Injection include Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC) injection, depending on the specific application.


Dosing and Procedural Requirements

Specific dosing and procedural constraints are utilized for proper use, particularly for reversing non-depolarizing neuromuscular blockade (NMB).

Administration Element Requirement
Standard NMB Dose Weight-based: 0.03 - 0.07 mg/kg of Neostigmine Methylsulfate.
Maximum Total Dose The dose must not exceed 5 mg in total.
IV Injection Speed Must be administered slowly over a period of at least 1 minute.
Concomitant Agents An anticholinergic agent (e.g., Atropine or Glycopyrrolate) must be administered prior to or concurrently with Neostigmine to mitigate muscarinic effects.
Age-Group Dosing Pediatric dosing follows the same mg/kg guidelines as adults for NMB reversal.

Procedural Structure

The required sequence for administration involves confirming the dose, preparing and co-administering the anticholinergic agent, injecting Neostigmine slowly, and maintaining post-administration respiratory monitoring. For continuous treatment (e.g., postoperative regimens), the injection follows a prescribed schedule, such as every 3 to 6 hours for a limited course.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

A. Core Mechanism Research

Research has examined the action of the drug. Studies have investigated the drug's properties in relation to receptors involved in the body's inflammatory response. Early-stage studies evaluated whether the drug was associated with a change in symptoms of the condition being investigated.

  • Mechanism of Action: Studies have focused on how the drug's components are processed, particularly on the influence on signaling pathways that enhance nerve-muscle communication.
  • Pharmacokinetics: Research evaluated the combined effect of the injection's components, noting that the formulation may influence absorption. Studies examined whether this was associated with a reduction of certain physiological activities, such as inflammation.

B. Clinical Trial Findings

Clinical research has investigated the drug's effects across various patient populations and disease stages.

1. Acute Symptom Management

Randomized Controlled Trials (RCTs) evaluated the effect on acute symptoms, with some studies noting changes within the study period, particularly in the reversal of neuromuscular blockade following surgery.

  • Primary Outcome Analysis: In placebo-controlled trials, studies reported an outcome difference compared to placebo. Secondary analysis explored whether this may correlate with a change in the severity of flare-ups of conditions like acute colonic pseudo-obstruction (Ogilvie's syndrome).
  • Dose Response: Trials assessed how variations in dosage might influence study outcomes, with mixed findings depending on the specific symptom or condition measured.

2. Long-Term Data

Fewer studies have focused on the long-term potential of the drug due to its primary use in acute, supervised settings. Studies have investigated the potential to affect long-term outcomes, such as disease progression or the need for other therapeutic interventions in chronic conditions like myasthenia gravis.

C. Safety and Tolerability Profiles

Research includes findings on tolerability and safety profiles. These studies primarily describe anticipated effects related to the mechanism of action.

  • Drug-Drug Interactions: Specific studies evaluated the potential for interaction with commonly prescribed medications, such as blood thinners and certain anti-depressants. Research noted that concomitant use was examined to understand its influence on drug levels in some participants.
  • Special Populations:
    • Pediatrics: Research also includes findings in pediatric patients. Data exploring the drug’s potential effects in children under 12 remain limited.
    • Elderly Patients: Studies have examined whether advanced age might correlate with a difference in the clearance of the drug from the body.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neostigmine Injection BP (FAQ)


Q: What is Neostigmine Injection BP primarily used for in hospitals?

A: According to official product information, Neostigmine Injection BP is primarily indicated for two main uses. The first is to reverse the effects of certain muscle-relaxing medicines (non-depolarizing neuromuscular blocking agents) given during surgery. The second official indication is for the prophylaxis (prevention) and management of postoperative urinary retention and intestinal atony, conditions where the bladder or bowel muscles are temporarily weak after an operation.


Q: Can Neostigmine Injection BP be used for bladder control issues?

A: Yes, official documents indicate that this medicine is indicated for the prophylaxis (prevention) and management of post-operative urinary retention. This indication relates specifically to post-operative urinary retention, which is described in official documents.


Q: What evidence supports the use of Neostigmine for myasthenia gravis?

A: Neostigmine is officially indicated as a treatment for myasthenia gravis, particularly during acute periods of severe muscle weakness. This use is based on its classification as a reversible anticholinesterase agent, which is intended to improve muscle strength and function.


Q: What does 'reversible anticholinesterase' mean in simple terms?

A: Neostigmine is classified as a reversible anticholinesterase agent. This means it acts to temporarily inhibit the breakdown of acetylcholine, which is a chemical messenger (neurotransmitter) essential for nerve cells to communicate with muscles.


Q: Is Neostigmine Injection BP used for chronic conditions or only short-term?

A: Official indications show it is used both for short-term purposes, such as reversing the effects of muscle relaxants given during surgery, and for the longer-term management of conditions like myasthenia gravis, which is a chronic condition.


Q: Why is Neostigmine used after some surgeries?

A: It is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs). These NMBAs are muscle-relaxing medicines often given during surgery, and Neostigmine is administered to assist in restoring muscle function and breathing capacity after the procedure is finished.


Q: How is the need for Neostigmine Injection BP determined by a physician?

A: When the medicine is used for the reversal of muscle relaxation after surgery, official procedures involve the physician using a peripheral nerve stimulator. This device helps evaluate the extent of recovery of muscle function, which guides the appropriate timing and dose for the injection.


Q: What happens to Neostigmine in the body once it's injected?

A: Official pharmacokinetic data indicates that Neostigmine is primarily metabolized (broken down) by microsomal enzymes in the liver. Once processed, the medicine is mainly eliminated from the body by the kidneys.


Q: How quickly does Neostigmine Injection BP start working?

A: Official documents do not provide a specific time for the onset of the therapeutic effect. However, the elimination half-life—the time it takes for half the drug to be processed—is reported to be between 24 and 113 minutes following intravenous injection, which is a measure of the rate at which the drug is processed and removed from the body.


Q: How long do the effects of Neostigmine injection last?

A: The elimination half-life following intravenous injection is reported in official pharmacokinetic data to be between 24 and 113 minutes. This figure provides an indication of the rate at which the medicine is processed and removed by the body.


Q: What kind of monitoring is needed after a Neostigmine injection?

A: Continuous monitoring of the patient's blood pressure and electrocardiogram (ECG) is generally advised, particularly for individuals with existing cardiac conditions. The patient is also monitored for the adequacy of the reversal of muscle relaxation.


Q: Can children or older adults receive Neostigmine Injection BP?

A: Official documents include established dosing guidelines for its use in pediatric patients. For older adults, the label does not specify distinct dose adjustments, but notes that existing health issues common in this group (such as heart conditions) require caution and continuous monitoring.


Q: What conditions make someone unable to use Neostigmine Injection BP?

A: According to official contraindication sections, Neostigmine Injection BP is contraindicated (should not be administered) if an individual has a known hypersensitivity (severe allergic reaction risk) to the drug. It is also contraindicated if the patient has peritonitis (abdominal inflammation) or a mechanical obstruction of the urinary or intestinal tracts.


Q: What is the difference between Neostigmine and atropine when used together?

A: Neostigmine works to increase a nerve messenger called acetylcholine. Atropine, an anticholinergic agent, is typically administered concurrently to lessen the risk of excessive cholinergic effects that Neostigmine causes, such as a slow heart rate (bradycardia) and increased secretions.


Q: Can Neostigmine Injection BP make muscle weakness worse?

A: Yes, official warnings state that the administration of large doses of Neostigmine, particularly when existing muscle weakness (neuromuscular blockade) is minimal, has been associated with neuromuscular dysfunction, which may present as increased muscle weakness.


Q: What are the most common side effects people notice after the injection?

A: Common adverse reactions listed in the official labeling include bradycardia (slow heart rate), nausea, vomiting, increased salivation, abdominal cramps, and diarrhea. These are expected effects related to the medicine's action on the body's involuntary nervous system.


Q: What are the serious, but rare, side effects of Neostigmine Injection BP?

A: Serious adverse reactions described in the official labeling include anaphylaxis (a severe allergic reaction), various cardiovascular complications (such as cardiac arrest or syncope), and a condition known as Cholinergic Crisis.


Q: Why does the drug literature mention 'cholinergic crisis'?

A: Cholinergic crisis is mentioned in the warnings section as a potential form of toxicity caused by overdosage. This condition leads to severe symptoms like extreme muscle weakness and is noted as requiring immediate medical intervention.


Q: Can Neostigmine Injection BP affect heart rate?

A: Yes, official warnings state that Neostigmine is associated with bradycardia (slow heart rate) and other cardiovascular complications, which is why an anticholinergic agent (such as atropine) is typically administered concurrently to mitigate this effect.


Q: Does Neostigmine Injection BP cause stomach issues or nausea?

A: Yes, common gastrointestinal adverse reactions listed in the official labeling include nausea, vomiting, abdominal cramps, and diarrhea. These are known effects related to its action on the body's involuntary nervous system.


Q: Is it normal to have increased salivation or sweating after the injection?

A: Yes, increased salivation and sweating are both listed as known adverse drug reactions. These are effects that commonly result from the drug's chief pharmacological action, which is to increase the amount of acetylcholine in the body.


Q: Is it common to feel dizzy or lightheaded after the injection?

A: Dizziness is listed as a nervous system disorder adverse reaction that has been reported following administration. This information is intended for educational purposes only.


Q: Can Neostigmine Injection BP affect sleep?

A: Insomnia (inability to sleep) is listed in the official adverse reactions section as a psychiatric disorder that has been reported in patients receiving the medicine.


Q: Can Neostigmine Injection BP cause allergic reactions?

A: Yes, official warnings state that hypersensitivity reactions, including a severe type of allergic reaction called anaphylaxis, have been reported with neostigmine.


Q: Are there any common medications that interact with Neostigmine Injection BP?

A: Interactions are noted with certain drugs that have neuromuscular blocking activity (such as aminoglycosides). Warnings also exist regarding drugs that have the potential to worsen myasthenia gravis, such as certain beta blockers.


Q: Does Neostigmine Injection BP interact with blood thinners?

A: While the labeling does not specifically list common blood thinners (anticoagulants) as a direct contraindication or interaction, the official document warns that other medicines may potentially reduce the overall effectiveness of Neostigmine.


Q: Does Neostigmine Injection BP interact with herbal supplements?

A: The patient information provided in the labeling advises individuals to give their healthcare provider a complete list of all medicines, herbs, non-prescription drugs, or dietary supplements they use, indicating that potential interactions should be reviewed by a professional.


Q: Do specific foods or drinks need to be avoided while using Neostigmine?

A: The official labeling advises patients to discuss the use of food, alcohol, or tobacco with a healthcare professional. No specific food is listed as a contraindication in the primary warnings.


Q: Are there any long-term side effects associated with Neostigmine Injection BP use?

A: The official labeling reports adverse reactions that may occur during treatment. However, specific long-term animal studies to evaluate effects like carcinogenic potential have not been conducted for neostigmine methylsulfate.


Q: How is Neostigmine Injection BP stored before it's used?

A: The product information states that the medicine is generally required to be stored below 25 C (77 F).


Q: Does Neostigmine Injection BP have a black box warning?

A: The US FDA labeling does not contain a specific black box warning. However, it does include several serious Warnings and Precautions, such as those concerning potential issues like bradycardia (slow heart rate) and cholinergic crisis.


Q: What is the risk of having a bad reaction to Neostigmine Injection BP?

A: The official labeling lists adverse reactions by frequency, with common reactions including bradycardia and nausea/vomiting. It also specifies serious but rare reactions, such as anaphylaxis.

Advertisements

How should Neostigmine Injection BP be stored and disposed of?

Neostigmine Injection BP must be stored according to strict regulatory conditions to ensure its stability.

Storage Requirement Official Condition
Temperature Store at or below 25 C; do not freeze.
Light Protection Protect from light; keep in the original outer carton.
Child Safety Keep out of the sight and reach of children.

The injection is intended for single use only. Any solution remaining in an opened container must be discarded immediately. If diluted, the stability of the solution cannot be guaranteed. Unused or expired product and waste material must be disposed of in accordance with local regulations and should not be discarded into wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neostigmine Injection BP found in:

A-Z Index: